Truist Financial Raises Eli Lilly and Company (NYSE:LLY) Price Target to $1,376.00

Eli Lilly and Company (NYSE:LLY) had its price target increased by equities researchers at Truist Financial from $1,370.00 to $1,376.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Truist Financial’s target price points to a potential upside of 18.17% from the stock’s current price.

Other research analysts have also recently issued research reports about the company. BMO Capital Markets reissued an “outperform” rating and issued a $1,400.00 price objective on shares of Eli Lilly and Company in a research note on Thursday. Jefferies Financial Group lifted their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a research report on Tuesday, June 9th. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. UBS Group increased their price target on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Finally, The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 price target on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Two analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,293.93.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,164.39 on Friday. The stock has a market cap of $1.10 trillion, a price-to-earnings ratio of 39.42, a price-to-earnings-growth ratio of 1.41 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,249.45. The firm has a 50-day moving average of $1,157.76 and a two-hundred day moving average of $1,046.57.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 103.84%. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts forecast that Eli Lilly and Company will post 36 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in LLY. Willner & Heller LLC increased its stake in Eli Lilly and Company by 1.0% during the 2nd quarter. Willner & Heller LLC now owns 917 shares of the company’s stock valued at $1,100,000 after buying an additional 9 shares during the period. Aspiring Ventures LLC boosted its holdings in shares of Eli Lilly and Company by 3.7% in the second quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock valued at $306,000 after acquiring an additional 9 shares in the last quarter. Wealthspan Partners LLC boosted its holdings in shares of Eli Lilly and Company by 0.4% in the second quarter. Wealthspan Partners LLC now owns 2,120 shares of the company’s stock valued at $2,543,000 after acquiring an additional 9 shares in the last quarter. Tanager Wealth Management LLP increased its stake in shares of Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after acquiring an additional 10 shares during the period. Finally, Morey & Quinn Wealth Partners LLC increased its stake in shares of Eli Lilly and Company by 1.5% during the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock valued at $710,000 after acquiring an additional 10 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported second-quarter revenue of approximately $22.97 billion, up 47.7% year over year and well above consensus estimates. Adjusted earnings of $8.38 per share also exceeded expectations by a wide margin. Eli Lilly Stock Remains a Buy after Q2
• Positive Sentiment: Mounjaro sales rose 91%, while Mounjaro and Zepbound together generated nearly $15 billion in quarterly revenue. The performance highlights Lilly’s widening advantage in the diabetes and obesity-drug market. Eli Lilly Raises 2026 Outlook Again
• Positive Sentiment: Management raised full-year 2026 revenue guidance to approximately $85 billion–$87 billion from $82 billion–$85 billion and maintained an earnings outlook of $35.50–$36.50 per share. Foundayo adoption, broader Medicare obesity-drug access and international expansion provide additional growth drivers. LLY Q2 Earnings Call Raises Outlook
• Positive Sentiment: Cantor Fitzgerald raised its price target to $1,410 and reiterated an “overweight” rating, reflecting continued Wall Street confidence after the beat-and-raise quarter. Cantor Fitzgerald Raises Eli Lilly Price Target
• Positive Sentiment: Lilly and Novo Nordisk prevailed in an antitrust lawsuit concerning the GLP-1 drug market, removing a potential legal overhang for Lilly’s obesity-treatment business. Lilly and Novo Defeat Antitrust Lawsuit

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.